- Oxford BioDynamics confirmed that it had joined a study designed to identify and measure specific biomarkers in people with amyotrophic lateral sclerosis.

The study was being sponsored by Mitsubishi Tanabe Pharma America and led by Massachusetts General Hospital's Neurological Clinical Research Institute.

It was expected to begin in late spring of 2019, with early interim analyses planned for later in the year.

Oxford BioDynamics said it may be able to offer insights on disease progression and treatment effect, based on its technology platform to evaluate epigenetic and protein biomarkers.

Biomarkers including oxidative stress, inflammation, neuronal injury and muscle injury, as well as clinical assessments, would be obtained from up to 300 patients in the US prior to initiating treatment with edaravone.

At 2:50pm: [LON:OBD] Oxford Biodynamics Plc share price was +3.5p at 151.5p

Story provided by